anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The current standard treatment will be prescribed, i.e. a 3D-conformal radiotherapy of a single fraction dose of 8.0 Gy to the metastasis with a planning target volume (PTV) margin for set-up and positioning uncertainties of 1 cm. This can be performed at any linear accelerator.
The present invention discloses Miao medicine for treating tuberculosis and rheumatic heart diseases and the methods of preparation and use thereof. The Miao medicine is prepared from peach kernels, almonds, fructus crotonis, peppers, agaric, ginger as effective components by adding egg white. The quality compounding ratio of medicinal materials is 1.8 to 2.5 of the peach kernels, 1.8 to 2.5 of the almonds, 1.8 to 3 of the fructus crotonis, 0.65 to 1 of white peppers, 3.7 to 7 of agaric and 18 to 22 of the ginger. The present invention has the preparation method that the dried agaric is firstly soaked by boiled water, is washed and cut for standby; a hole is drilled on an egg to flow out the egg white for concentrating standby. The peach kernels, the almonds, the fructus crotonis, the pepper and the ginger are proportionally crushed into fine powder. The agaric is added for mixing, and the egg white is used for evenly mixing. After even stir, pasty medicine is obtained. During use, the Miao medicine is painted on white cloth and is coated on a concave part of a foot sole. The Miao medicine has the advantages of unique formula, unique use methods and good curative effects.
Phenoxybenzyl esters of formula (I) (where R1 is ethyl, n-propyl or isopropyl and R2 is H or CN), are new: Also new are intermediates of formula (II) (where Y is OH or halo and R1' is lower alkyl), and their optical isomers. (I) are insecticides and acaricides having contact, and systemic activities. They can be used to protect agricultural prods. during growth and after harvesting, and for systemic protection (by oral or parenteral administration of animals. They are esp. active against mosquitoes and tobacco caterpillars.
Consult with a Certified Poison Control Center for up-to-date guidance and advice. Management of acute amphetamine intoxication is largely symptomatic and includes gastric lavage, administration of activated charcoal, administration of a cathartic, and sedation. Experience with hemodialysis or peritoneal dialysis is inadequate to permit recommendation in this regard. Acidification of the urine increases amphetamine excretion, but is believed to increase risk of acute renal failure if myoglobinuria is present. If acute, severe hypertension complicates amphetamine overdosage, administration of intravenous phentolamine has been suggested. However, a gradual drop in blood pressure will usually result when sufficient sedation has been achieved.

Chlorpromazine antagonizes the central stimulant effects of amphetamines and can be used to treat amphetamine intoxication.
The disclosure provides methods and constructs for the stable production and isolation of biologically functional recombinant V3, a splice variant of the extracellular matrix proteoglycan versican, as well as the protein product and reagents for detecting the same. In one embodiment, the disclosure provides expression systems for expressing rV3. In one embodiment, the disclosure provides an expression system that properly N-glycosylates mammalian proteins, such as V3. In another embodiment, rV3 has been isolated and purified. In another embodiment, the disclosure provides a unique expression construct containing a ubiquitous chromatin opening element upstream of a strong promoter which drives expression of recombinant V3. In yet a further embodiment, the disclosure provides an isolated and purified recombinant V3 protein in amounts suitable for testing and use, and in pharmaceutical compositions thereof.
Several studies have suggested that mutation of the interleukin 36 receptor antagonist gene (IL36RN) is related to generalized pustular psoriasis (GPP), and the presence of IL36RN mutation may affect the clinical manifestations and treatment responses. However, genetic testing is not routinely available in clinical practice for the diagnosis of GPP. Previously, GPP patients with acrodermatitis continua of Hallopeau (ACH) were found to have a high percentage of carrying IL36RN mutation. In this study, we reported six patients with pustular psoriasis presenting as diffuse palmoplantar erythema with keratoderma among 60 patients who carried IL36RN mutation. ACH was present in five patients and five patients had acute flare of GPP. This unique presentation may serve as a predictor for IL36RN mutation in patients with pustular psoriasis, similar to ACH.
The invention discloses a new effect of paeonol, namely the inhibition effect of the paeonol on malassezia. Paeonol is a plant extract, and can be used for treating dandruff, scalp pruritus, etc. caused by malassezia. Compared with the common synthetic anti-dandruff agent, the paeonol has the characteristics of mildness, no stimulation, safety, high efficiency and environmental friendliness. Shampoo and anti-dandruff preparation prepared by taking the active ingredients have good efficacy and market prospect. The invention also discloses a preparation method of the paeonol nanoemulsion, so that the paeonol can be conveniently applied to personal care products, particularly transparent products.
Washing-leaflets are made from a mixture of a sulphonate of a fat alcohol, or a derivative thereof, and a colloidally water-soluble alkyl ether, e.g. the dimethyl ether of cellulose sold under the trade name Colloresin.  Perfumes or disinfectants may be added, and the leaflets may be put up in book form.  The Specification as open to inspection under Sect. 91 describes the use of a mixture of 10-70 per cent of Colloresin F.S. with 90-30 per cent of the sulphonated fat-alcohol product sold under the trade name of Texapon, and specifies up to 2,0 per cent of essential oils of B.P. above 75 DEG C. as suitable perfumes, up to 1 per cent of formaldehyde and cresol as suitable disinfectants. This subject-matter does not appear in the Specification as accepted.
After being informed about the study and potential risks, all participants giving written informed consent will answer questions about themselves and complete a 12-question survey about the need for drama. An examiner will then measure the sensitivity of the cornea (clear window on the front of the eye) by touching the cornea with a thin thread that shortens until it is first detected by the participant. After that, an examiner will place a drop of atropine in the right eye, and the participant will rate the eye comfort for 25 seconds using a computerized slide scale. Five minutes after the first drop, the examiner will put a drop in the left eye and the participant will rate the comfort for 25 seconds. The examiner will then repeat that process one more time with each eye. The drops placed in the eyes will be 0.01% atropine at room temperature from Lab A, 0.05% atropine at room temperature from Lab A, 0.05% atropine refrigerated from Lab A, or 0.05% atropine at room temperature from Lab B. The drops will be placed in the eyes in random order, so the participant won't know which one is being administered. At the very end, the participant will rate how likely s/he would be to take a low concentration atropine eye drop every day in each eye if it may delay the onset of nearsightedness from 1 (definitely not) to 10 (definitely would).
A prospective, observational, convenience sample of trauma patients 18 years old or older who present to the trauma bay as a trauma alert will be included after evaluation by the on-call trauma surgeon and research assistant. Minimally injured patients will be compared to those with a systolic blood pressure of 90 mmHg or less, the need for blood product transfusion within 1 hour of admission, and/or an ISS (injury severity score) of greater than or equal to 15. Demographic data including past medical/medication history as well as clinical data including continuous vital signs will be recorded. If eligibility criteria are met, the research blood samples will be drawn at the same time as routine clinical samples. Blood samples (approximately 15 ml) will be taken on admission, 3hr, 6hrs, 12hrs, 24 hrs, 48 hrs, and 5 days post admission. Vital signs, number of blood transfusions, volume of crystalloid, administration of medications, and the values of routine laboratories will be monitored continuously for 24 hours, and then cumulatively for up to 5 days. After the last blood draw, we will be following the patient's outcome for up to 30 days. If patients are discharged or die prior to completing the 5 days of blood samples, additional samples and/or clinic appointments for the purpose of research will not be obtained. A computational algorithm will be used to predict the development of trauma induced coagulopathy, inflammation and multi-organ failure.
Systemic absorption of bupivacaine produces effects on the cardiovascular system and CNS. At blood concentrations achieved with normal therapeutic doses, changes in cardiac conduction, excitability, refractoriness, contractility, and peripheral vascular resistance are minimal. However, toxic blood concentrations depress cardiac conduction and excitability, which may lead to atrioventricular block, ventricular arrhythmias, and cardiac arrest, sometimes resulting in fatalities. In addition, myocardial contractility is depressed and peripheral vasodilation occurs, leading to decreased cardiac output and arterial blood pressure. 

These cardiovascular changes are more likely to occur after unintended intravascular injection of bupivacaine [see Warnings and Precautions (5.4)].

Following systemic absorption, bupivacaine can produce CNS stimulation, CNS depression, or both. Apparent central stimulation is manifested as restlessness, tremors and shivering, progressing to convulsions, followed by CNS depression and coma progressing ultimately to respiratory arrest. However, bupivacaine has a primary depressant effect on the medulla and on higher centers. The depressed stage may occur without a prior excited stage.

The duration of local anesthesia after administration of Bupivacaine Hydrochloride in Dextrose Injection is longer than that observed after administration of other commonly used short-acting local anesthetic. There appears to be a period of analgesia that persists after the resolution of the block and the return of sensation.

The onset of sensory blockade following spinal block with Bupivacaine Hydrochloride in Dextrose Injection is rapid (generally within one minute); maximum motor blockade and maximum dermatome level are achieved within 15 minutes in most cases. Duration of sensory blockade (time to return of complete sensation in the operative site or regression of two dermatomes) following Bupivacaine Hydrochloride in Dextrose Injection 12 mg averages 2 hours with or without 0.2 mg epinephrine. The time to return of complete motor ability with Bupivacaine Hydrochloride in Dextrose Injection 12 mg averages 3.5 hours without the addition of epinephrine and 4.5 hours if 0.2 mg epinephrine is added. When compared to equal milligram doses of hyperbaric tetracaine, the duration of sensory blockade was the same, but the time to complete motor recovery was longer for tetracaine. Addition of 0.2 mg epinephrine prolongs the motor blockade and time to first postoperative opioid with Bupivacaine Hydrochloride in Dextrose Injection.
Escherichia coli is a Gram-negative bacterium that causes a variety of clinical infections in humans, including diarrhea, sepsis, and urinary tract infection. This bacterium is a common multidrug-resistant threat in community and hospital settings worldwide. This study examined the antimicrobial susceptibility and genetic relationship based on Clermont phylotyping and enterobacterial repetitive intergenic consensus (ERIC)-PCR of 84 E. coli urinary isolates from provincial and community hospitals in Thailand. All isolates were susceptible to nitrofurantoin, and almost all isolates were susceptible to carbapenem, fosfomycin, and amikacin. High resistance rates to fluoroquinolone, ampicillin, and trimethoprim/sulfamethoxazole were observed. Clermont phylogroup B2 was predominant (n = 58). Subtyping of the B2 phylogroup revealed diverse subgroups, of which subgroup V (n = 11), VII (n = 9), III (n = 6), and II (n = 6) were most prevalent. ERIC-PCR showed that the strains of the B2 subgroups III and V were spread between provincial and community hospitals and between hospital wards. This evidence suggests the need for comprehensive infection control monitoring, with strong active surveillance at all hospital levels.
Every patient who is scheduled for bariatric surgery in the university hospital Aachen will be evaluated for this study. After informed consent baseline measurements are performed preoperative. Baseline measurements involve blood and stool samples, LiMAx, FibroScan and ultrasound. During the operation a liver, a subcutaneous and visceral fat sample are taken to analyse liver histology and inflammation as well as fatty tissue signaling. After the operation patients are observed 24 month. Further blood samples are taken on the first postoperative day, 2 and 4 weeks, 3, 6, 12, 18 and 24 month after the operation. Stool samples are taken 2 and 4 weeks, 3, 6, 12, 18 and 24 month after the intervention. The LiMAx test, a test analysing the liver function, is performed 4 weeks, 6, 12 and 24 month after the operation. The morphologic liver structure is evaluated by FibroScan and ultrasound 4 weeks, 6, 12 and 24 month postoperative.
All patients undergo chemoradiation therapy comprising radiation therapy once daily 5 days a week for 5 weeks and fluorouracil intravenously continuously over 24 hours 7 days a week for 6 weeks. Patients undergo standard surgical resection after completion of chemoradiation therapy..
Patients will receive SRP-4053 placebo-matching IV infusions, weekly, for 12 weeks. Dosing will be interrupted or halted if specific predefined stopping criteria are met or if warranted at the discretion of the Sponsor or Investigator.
PURPOSE:To provide the titled clathrate compound having increased solubility and stability in water, by adding a solution of cyclodextrin to a lankacidin-group antibiotic substance. CONSTITUTION:The objective compound is a lankacidin-group antibiotic substance of formula I (R<1> is O, H or OH; R<2> and R<3> are H or lower alkanoyl) or formula II (R<4> is H or lower alkanoyl) included in a cyclodextrin (e.g. alpha, beta, gamma, delta-cyclodextrin). It can be prepared by adding the corresponding lankacidin to a solution obtained by dissolving a specific amount of the cyclodextrin in a solvent (e.g. water), stirring the mixture, and if necessary, separating the insoluble matter by filtration. The administration path of lankacidin has been limited because of its insolubility and instability in water, however, the compound can be easily stabilized and made soluble in water by this process. Accordingly, it can be administered by injection or as an oral drug, and the rate and the amount of absorption in the living body are increased.
The invention belongs to the technical field of biological medicines, and particularly discloses a fusion protein with multiple influenza A virus immunogenicity, and preparation and application thereof. The fusion protein is rM2 e-delta A146PLY protein, and sequentially comprises rM2e protein and delta A146PLY protein from the N end to the C end, wherein the rM2e protein comprises four public sequences derived from poultry, pigs and human influenza A virus M2e protein, and the sequence of the public sequences is shown as SEQ ID NO. 5; the sequence of the delta A146PLY protein is shown as SEQ ID NO. 8; the rM2 e-delta A146PLY protein sequence is SEQ ID NO: shown at 10. The invention discovers that the delta A146PLY protein has good adjuvant function, and the immunogenicity and the protective effect of the M2e protein can be obviously enhanced by connecting M2e protein segments in series to express and connecting the N end of the delta A146PLY protein. The fusion protein provided by the invention has the potential of being developed into a universal vaccine of influenza A virus.
BACKGROUND: Chronic pain is a major health problem that affects a significant number of patients, resulting in personal suffering and substantial health care costs. One of the most commonly reported causal conditions is osteoarthritis (OA). In addition to sensory symptoms, chronic pain shares an inherent overlap with mood or anxiety disorders. The involvement of the frontal cortex, striatum and nucleus accumbens, in the affective processing of pain is still poorly understood.
METHODS: Male Wistar rats were divided into two groups: MIA (monoiodoacetate injected into the knee-model of OA) and sham (NaCl). Behavioral tests assessing pain, anxiety, and depressive behavior were performed at week 1, 3, 4, 6, 8, and 10. Neurochemical assays were conducted at weeks 3, 6, and 10 post-MIA injection, followed by the neurotransmitters and their metabolites correlation matrix and network analysis.
RESULTS: OA animals developed rapid pain phenotype, whereas anxiety-like behavior accompanied the development of a pain phenotype from 6 week post-MIA injection. We did not detect any depressive-like behavior. Instead, immobility time measured in the forced swimming test transiently decreased at 3 weeks post-MIA in the OA group. We detected changes in noradrenaline and serotonin levels in analyzed structures at distinct time points. Network analysis revealed noradrenaline and serotonin neurotransmission changes in the nucleus accumbens, confirming it to be the key structure affected by chronic pain.
CONCLUSION: Animals with chronic pain exhibit symptoms of anxiety-like behavior and we identified underlying neurochemical changes using network analysis.
Evaluate women for ectopic pregnancy if they become pregnant with Mirena in place because the likelihood of a pregnancy being ectopic is increased with Mirena. Approximately one-half of pregnancies that occur with Mirena in place are likely to be ectopic. Also consider the possibility of ectopic pregnancy in the case of lower abdominal pain, especially in association with missed menses or if an amenorrheic woman starts bleeding. 

The incidence of ectopic pregnancy in clinical trials with Mirena, which excluded women with a history of ectopic pregnancy, was approximately 0.1% per year. The risk of ectopic pregnancy, in women who have a history of ectopic pregnancy and use Mirena is unknown. Women with a previous history of ectopic pregnancy, tubal surgery or pelvic infection carry a higher risk of ectopic pregnancy. Ectopic pregnancy may result in loss of fertility.
Virtual reality immersive intervention: 1-week virtual reality self-help exposure-based intervention. Participants will be asked to use the assigned virtual environment for a minimum of three times in total over the week, at home.
Chronic daily headache in children, as well as periodic migraine, is a prevalent, persistent, and debilitating pain condition affecting nearly 1 in 10 children. Emerging evidence suggests that affected youth also experience excessive and impairing symptoms of anxiety which may play a role in the etiology and/or maintenance of headache pain. Current behavioral treatments are effective in reducing headache frequency and intensity, however, many youth remain symptomatic and the exacerbating role of anxiety has largely been ignored. Moreover, current psychosocial treatments fail to incorporate parents in the therapeutic process. The current proposal is a pilot study designed to address the shortcomings of current behavioral treatments by evaluating the initial efficacy of a family-based cognitive-behavioral therapy (CBT) for youth who present with chronic tension headaches and migraines, and excessive anxiety. Rigorous scientific methods will be employed, including a randomized design, multiple informants and measures to assess key constructs, independent evaluators (IEs) to assess outcomes, and intensive training for therapists and IEs to assure a high quality of implementation. Using a pre-post experimental design, 30 youth with chronic tension headaches and/or migraines and anxiety will be randomly assigned to receive 8 weeks of family-based CBT or relaxation training (RT). IEs will complete assessments of child symptoms and functioning at pre and post-treatment and at one month follow-up. Youth in the family-based CBT condition are expected to evince greater reductions in both headache and anxiety frequency, severity, and duration. Results from this study will be used to make empirically informed modifications to the CBT treatment manual in order to facilitate replication and dissemination of the interventions to clinicians and researchers.
FIELD: medicine. SUBSTANCE: this method for preventing atrophy of testicle after rupture of tunica albuginea prescribes administering riboxine in daily dosage of 25 mg/kg immediately after injury has been received or 72 h prior to planned operation and during 30 days. Experiment involving operated testicle model has revealed the fact that disclosed method permits preserving normal amount of sex cells in ductules, fission of spermatogenic epithelium cells and normal completion of development cycle, formation of normal mature spermatozoa inclusive. At the same time, disclosed method favors preservation of endocrinic functionability of testis what can be judged by higher content of testosterone in blood plasma and greater index of relative percentage of testosterone and lutropine. Variations in all evaluated parameters of patients treated with riboxine and controls are certain with P not greater than 0.05. EFFECT: disclosed method is advantageous whenever there arise necessity in preserving male reproductive function in all cases intactness of tunica albuginea is disturbed. 1 tbl
Hypertension: Dosage needs to be adjusted by titration to individual patient needs. When used as monotherapy, usual starting doses are 120 to 240 mg once daily. Maximum antihypertensive effect is usually observed by 14 days of chronic therapy; therefore, dosage adjustments should be scheduled accordingly. The usual dosage range studied in clinical trials was 120 to 540 mg once daily. Current clinical experience with 540 mg dose is limited; however, the dose may be increased to 540 mg once daily.

Angina: Dosages for the treatment of angina should be adjusted to each patient's needs, starting with a dose of 120 mg to 180 mg once daily. Individual patients may respond to higher doses of up to 540 mg once daily. When necessary, titration should be carried out over 7 to 14 days.
A composition for treating a lysogenic virus, including a vector encoding isolated nucleic acid encoding two or more gene editors chosen from gene editors that target viral DNA, gene editors that target viral RNA, and combinations thereof. A composition for treating a lytic virus, including a vector encoding isolated nucleic acid encoding at least one gene editor that targets viral DNA and a viral RNA targeting composition. A composition for treating both lysogenic and lytic viruses, including a vector encoding isolated nucleic acid encoding two or more gene editors that target viral RNA. A composition for treating lytic viruses. A method of increasing specificity of gene editors in treating an individual for a virus. Methods of treating a lysogenic virus or a lytic virus, by administering the above compositions to an individual having a virus and inactivating the virus.
Participants were administered with placebo tablets matching to TAC-101 orally, every day on the first 14 days (Days 1 to 14) followed by a 7-day (Days 15 to 21) treatment recovery period. Repeated every 21 days cycle up to new lesions were observed or the participant met a treatment discontinuation criterion.